They do have other potential blockbusters in the pipeline such as Garadacimab (CSL312), a novel, fully-human monoclonal antibody that inhibits activated factor XII (FXIIa), for the prevention of hereditary angioedema attacks. Phase III trials complete. Forecast to add $50 to share price
CSL Price at posting:
$271.91 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)